Zealand Pharma A/S (OTCMKTS:ZLDPF) (OTCMKTS:ZLDPF) is a Denmark-based biotechnology company specializing in the discovery, development and commercialization of peptide-based medicines. The company’s primary focus is on metabolic and endocrine disorders, particularly in diabetes and rare hormone-related diseases. Zealand leverages its proprietary peptide engineering platform to optimize therapeutic profiles, enhancing stability, selectivity and patient convenience across its product portfolio.
One of Zealand Pharma’s flagship products is dasiglucagon, a next-generation, stable glucagon analog approved for the treatment of severe hypoglycemia. Marketed under the brand name Zegalogue in key regions, dasiglucagon addresses critical unmet needs in diabetes management by offering a ready-to-use, room-temperature‐stable formulation. Beyond its approved product, the company maintains a robust pipeline that includes long-acting amylin analogs, novel GLP-1 receptor agonists and other hormone modulators designed to improve glycemic control and reduce cardiovascular risk.
Collaboration is central to Zealand’s business model. The company has entered into strategic partnerships and licensing agreements with leading pharmaceutical firms such as Novo Nordisk, Sanofi and Boehringer Ingelheim. These alliances leverage Zealand’s peptide expertise and its partners’ global commercialization networks, facilitating market access in North America, Europe and Asia, including Japan. In addition to collaborative R&D, Zealand operates manufacturing partnerships to support clinical and commercial supply chains.
Founded in 1998 and headquartered in Copenhagen, Zealand Pharma has grown from an academic spin-off into a publicly traded enterprise listed on Nasdaq Copenhagen, with ADRs trading over the counter in the U.S. The leadership team is headed by CEO Emmanuel Dulac, supported by a seasoned executive management group and an experienced board of directors. Under their guidance, Zealand continues to advance its mission of delivering innovative peptide therapeutics to patients worldwide.
